Conference Introduction

The 2nd International Nanostructured Magnetic Beads and Biomedical Forum will be held on March 1-2, 2023 at Suzhou Industrial Park International Expo Center. This academic forum will invite more than 30 renowned specialists and business executives in the field of magnetic nanomaterials and biomedical sciences in domestic and international to make keynote presentations. This meeting is aiming to build a platform for technical cooperation and communication between scientists and industry in related fields. Meanwhile, the promotion of the synergistic development of magnetic nanoparticles and biomedicine is expected. The conference also fully demonstrates the most cutting-edge research results and technological needs in these two fields.

The first International Nanostructured Magnetic Beads and Biomedical Forum has been successfully held in Suzhou on Dec. 10~11, 2021. The conference invited 31 well-known experts and industry leaders from home and abroad to make wonderful reports. The forum attracted more than 3,000 professionals in the industry to attend and join the discussion. It also successfully built a comprehensive platform for policy discussion, academic exchange and project cooperation.

Both academic forums are sponsored by Suzhou BEAVER Biomedical Engineering Co. BEAVER was established in 2011 in Suzhou, the "Entrepreneur's Paradise", and is one of the first companies in China to concentrate on the development and industrialization of magnetic nanoparticles, the core material of biomedicine. After ten years of development, as well as the trust and help of users and many partners, hundreds of products have entered the market and are gradually being widely used in scientific research, in vitro diagnostics, analytical testing and food and drug safety testing.

Conference Organizers

Conference Organizers

Hosts

    • BEAVER Biomedical Engineering Co., Ltd.

Co-organizers

    • Labeled Immunoassay Committee of Chinese association of Instrumental Analysis 
    • Suzhou Nano Advanced Materials Association
    • Nanopolis Suzhou Co., Ltd.


Main Topics

Main Topics

Agenda arrangement

Agenda arrangement

Date: Mar.1
Location: A206-A207
Date: Mar.2
Location: A206-A207
  • Biomedical Session Section 3
    Host: Yili Yang,DirectorI of International Center for Genetic Engineering and Biotechnology

  • 08:30-08:50
    Next Generation NK Cell Activation and Amplification System
    Lin Guo, CAR-NK Researcher of Innovent Biologics, Inc.

  • 08:50-09:10
    New Trends in the Development of Cell Culture Media in the Field of Cell and Gene Therapy
    Shiqi Ma, Application Scientist of Suzhou ExCell Biotechnology Co., Ltd.

  • 09:10-09:30
    Study on Cancer Nano-Vaccine Reassembled from Whole Cell Components of Cancer Cells and Delivery of mRNA by Lipid Micro-Particles
    Mi Liu,Professor, Soochow University

  • 09:30-09:50
    The Testing Strategy and Sterile Rapid Testing of Original Supplementary Materials for Quasi-Commercial Cell Therapy Drug
    Jingwei Zhu, Qulity Director of Jiangsu Hillgene Biomedical Co., Ltd.

  • 09:50-10:10
    Application of Immunomagnetic Beads in Cell Isolation and Activation
    Chao Hong,Associate Professor, Soochow University / Principal Engineer of BEAVER Biomedical Engneering Co., Ltd.

  • 10:10-10:30
    Tea Break

  • Biomedical Session Section 4
    Host: Mu Wang,Professor, Xi'an Jiaotong-Liverpool University

  • 10:30-10:50
    Application of Humanized Immunity System Mice in the Development of Nano-vaccine
    Jing Huang,Chairman of Next Vivo Suzhou Biotechnology Co., Ltd.

  • 10:50-11:10
    Advances in mRNA Vaccine Technology
    Peng Gao,VP of Suzhou Abogen Biosciences Inc.

  • 11:10-11:30
    The Platform Establishment and Application for Exosome Based Drug Development
    Ke Xu,Chairman & CEO of VesiCURE Therapeutics. Co., Ltd.

  • 11:30-11:50
    DNA Storage ---- Concepts and Applications
    Di Liu, Professor, Wuhan Institute of Virology, Chinese Academy of Sciences

  • 11:50-12:10
    Multi-Omics Based Tool Enzymes Exploration and Industrial Application
    Shancen Zhao,Vice President of The Beijing Genomic Institute- Research

  • 12:10-13:40
    Lunch

  • In Vitro Diagnostics Session Section 5
    Host: Luyang Tao,Full Professor, Soochow University

  • 13::40-14:00
    Current Situation and Future of Core Protein Materials Applied for IVD Industry
    Yongchang Qian,Chairman of Hangzhou NeuroPeptide Biological Science and Technology Incorporation, Ltd.

  • 14:00-14:20
    Early Cancer Screening using Artificial Intelligence assisted Immune Big Data Analyses (AIAIBDA)a
    Zhixin Zhang, Professor, University of Electronic Science and Technology of China / Chairman of Chengdu ExAb Biotechnology Co., Ltd.

  • 14:20-14:40
    Bio-Inspired Interfacial Materials with Controlled Adhesion
    Shutao Wang,Professor, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences

  • 14:40-15:00
    Developing Naturally Stress-Resistant Crops for a Sustainable Agriculture
    Heng Zhang,Professor, Shanghai Jiao Tong University

  • 15:00-15:30
    Tea Break

  • In Vitro Diagnostics Session Section 6
    Host: Li Zhu,Associate Professor,Hematology Center, Cyrus Tang Medical Institute

  • 15:30-15:50
    The Fibrotic Disease Drived by Bioinformatics Big Data
    Jin Su,Professor, Guangzhou Medical University

  • 15:50-16:10
    Development of a Nucleic Acid Extraction Kit for Pathogenic Bacteria using Concave Soil Material
    Yahui Guo,Associate Professor, Jiangnan University

  • 16:10-16:30
    Application of Novel Magnetic Beads Automation Technology in Food Safety Detection
    Jin Ye,Associate Professor, Academy of National Food and Strategic Reserves Administration

  • 16:30-16:50
    XploreSeq™——Explore Vast Antibody Sequence Space: NGS and AI Enabling Antibody Discovery
    Xingda Ye,Head of BioinformaticsAntibody Department of Shenzhen Jingtai Technology Co., Ltd.

Speakers
Li Zhu
(TBD)
TBD

 Biography: TBD
Abstract: TBD

Speakers
Di Liu
( Professor, Wuhan Institute of Virology, Chinese Academy of Sciences)
DNA Storage ---- Concepts and Applications

Biography:Dr. Di Liu received his Doctoral degree in bioinformatics from Peking University. Currently, he is a professor and principal investigator at Wuhan Institute of Virology, Chinese Academy of Sciences. His research area includes virus genomics & evolution, and bioinformatics. In 2018, his group began the study of DNA data storage and was supported by the National Key R&D Program. Dr. Liu has published over 140 research articles in journals including Nature, Lancet, New England Journal of Medicine, Cell Metabolisms, etc. He achieved an H-index of 43 in 2022.

Abstract: DNA storage technology, as an emerging big data storage technology, breaks through the solid media as the medium of storage and uses the natural information storage capacity of DNA bases to convert binary coded information into quadratic coded nucleic acid sequences according to certain rules, with high storage density, long retention time and ultra-low energy consumption, fundamentally changing the way of data preservation and transmission. The characteristics of DNA storage make it promising in the fields of long-term archiving of cold data, new data encryption and DNA computing.

Speakers
Shumei Zhang
( President of Suzhou Nano Technology Development Co., Ltd.)
TBD

 Biography: TBD
Abstract: TBD

Speakers
Guangtao Yan
(Chairman of the Labeled Immunoassay Professional Committee)
TBD

 Biography: TBD
Abstract: TBD

Speakers
Hui Ren
( Chairman & CEO of BEAVER Biomedical Engneering Co., Ltd.)
TBD

 Biography: TBD
Abstract: TBD

Speakers
Quan Yu
( Director of Antibody Engineering of Shenzhen Jingtai Technology Co., Ltd. )
XploreSeq™——Explore Vast Antibody Sequence Space: NGS and AI Enabling Antibody Discovery

Biography: XtalPi

Reistone Biopharma

Shanghai XBH biotechnology

Pharmalegacy Laboratories

Shanghai Benemae Pharmaceutical

Abstract: TBD

Speakers
Jin Ye
(Associate Professor, Academy of National Food and Strategic Reserves Administration)
Application of Novel Magnetic Bead Automation Technology in Food Safety Detection

Biography: Ye Jin is an Associate professor at the Academy of National Food and Strategic Reserves AdministrationChina. He has been engaged in the research on detection, monitoring and prediction of mycotoxins in grain for a long time. In 2018, he was selected as the fourth Youth Talent Promotion Project of China Association for Science and Technology; in 2020, he was reward as the second Youth Science and Technology Award of China Association of Grain and Oil; in 2022, he was selected as one of the first batch of top young talents of National food and materials reserve. He is an expert of the Working Group on Mycotoxins of the Sub-Committee on Cereals and Pulse of the International Organization for Standardization (ISO/TC 34/SC 4) and a member of the Chinese Delegation to the 15th Session of the Codex Alimentarius Commission on Contaminants in Food (CCCF15). He presided over 8 projects including National Natural Science Foundation and national key research and development project sub-projects, and participated in 5 national and provincial level projects as technical backbone.In the past five years, he has published more than 60 research papers in Food Chemistry, Journal of Agricultural and Food Chemistry, Journal of Hazardous Material and other domestic and foreign journals. He has completed the first ISO international standard for mycotoxin detection which is led by China, presided over and participated in the revision of 13 national and industrial standards, and 26 national certified reference materials. He has applied for 12 invention patents, including 4 authorized ones, and participated in the compilation of 3 monographs. He won the second Prize of Science and Technology Award of China Grain and Oil Society in 2022 (1/9), the first prize of Science and Technology Award of China Grain and Oil Society in 2021 (2/12), the special Prize of Science and Technology Award of China Federation of Commerce in 2020 (14/15), the second prize of Shennong Chinese Agricultural Science and Technology Award in 2020-2021 (8/15), 2017 China Association of Analysis and Testing Science and Technology Award first prize (5/9) and other academic awards.

Abstract: Based on the developed new immunoaffinity magnetic beads and automated processing technology, the automated magnetic beads food safety detection method was developed and standardized, which overcomes the traditional food safety detection method with high personnel requirements, long processing time and other disadvantages. The automatic processing effectively reduces human error, and comprehensively improves the detection efficiency and accuracy.

Speakers
Shutao Wang
(Professor, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences)
Bio-Inspired Interfacial Materials with Controlled Adhesion

Biography: Shutao Wang is a Professor at the Technical Institute of Physics and Chemistry, CAS. He is a Fellow of the Chinese Chemical Society (CCS) and Royal Chemical Society (RSC). He is also Vice Director of CAS Key Laboratory of Bio-inspired Materials and Interfacial Science.Research interests include bio-inspired multi-scale interfacial materials for controlled adhesion. Wang has revealed the mechanism of special adhesion phenomenon in nature, designed and prepared a series of bio-inspired multi-scale interfacial materials, and explored their applications in healthcare, energy, and information fields.He has published more than 270 SCI papers, including Nature, Nat. Mater., Nat. Commun., Nat. Protoc., Sci. Adv., Adv. Mater., Angew. Chem., J. Am. Chem. Soc., Proc. Natl. Acad. Sci. USA, Chem. Rev., Chem. Soc. Rev., Acc. Chem. Res., and Nat. Rev. Mater., with a citation over 24000 times. He has been selected as Global Highly Cited Research (Clarivate) for several times, been nominated for World Science and Technology Award (2010), and won many awards including CCS Young Chemist Award (2013), CAS Young Scientist Award (2017), Nano Research Young Innovators Award in NanoBiotech (45 under 45) (2018), et al.

Abstract: Interface adhesion regulation has continually been a difficult problem in the field of surface/interface physical chemistry. Learning from nature, we realized great achievements in the following three directions. (1) We proposed the concept of “structure matching and molecular recognition” for interfacial cell adhesion, constructed a series of interfacial adhesion materials, improved the clinical diagnosis accuracy of prostate cancer in PSA gray zone from 58.3% to 91.7%, which was written into the clinical diagnostic guidelines. (2) We proposed a new synthesis method for the preparation of microparticles by emulsion interfacial polymerization, and constructed a series of new biological separation microparticles, and realized the upgradation of polypeptide and protein separation microparticles except beyond cells. From traditional porous microspheres to heterostructured nanoporous microparticle and to heterostructured nanofractal microparticles, the separation selectivity and separation rate was improved, respectively. (3) We proposed a series of new strategies for the removal of liquid layer on solid surface, including interface water conduction method, medium solvent exchange method, etc., and developed a series of wet adhesion interfacial materials, providing solutions to the problem of the influence of interface liquid layer on wet adhesion.

Speakers
Yongchang Qian
(Chairman of Hangzhou NeuroPeptide Biological Science and Technology Incorporation, Ltd.)
Current Situation and Future of Core Protein Materials Applied for IVD Industry

Biography: QIAN YONGCHANGfounder and president/CEO of Hangzhou NeuroPeptide Biological Science and Technology Co. Ltd. (NUPTEC), received his bachelor’s degree from Fudan University, PhD degree from Chinese Academy of Sciences, and finished his postdoctoral training at UC Davis and Texas A&M University. Then, Dr. Qian was employed as an assistant professor, associate professor and PhD program adviser at Texas A&M University. During twenty years in USA, Dr. Qian had been working on research and teaching in the field of biomedical technology. He obtained several research funds from US NIH and US DOD, and published over 90 research papers. As an oversea senior talent recruited by Zhejiang provincial government, Dr. Qian founded the NUPTEC. Within more than ten years after Dr. Qian came back to China, he engaged in R&D and manufacturing on recombinant proteins and protein purification resins. Products is extensively utilized in downstream industries of IVD diagnosiscell culture, and biopharmaceutical manufacturing. He has been authorized for more then ten patents of invention in China.

Abstract: The technique in precision IVD diagnosis needs different categories and properties of key materials, including proteins, for instance, streptavidin (SA), antibodies, antigens, and enzymes. With the development of molecular genetics and molecular biological techniques, proteins can be engineered at molecular genetic level and molecular biological level in the biological systems in vivo, but also they can be modified by techniques of organic chemistry in vitro. Therefore, proteins, one of key materials, can play an extremely important role in precision IVD diagnosis.

Speakers
Ke Xu
(Chairman & CEO of VesiCURE Therapeutics. Co., Ltd.)
The Platform Establishment and Application for Exosome Based Drug Development

Biography: Dr. Xu got his Ph.D. dgree in Genetics & Development from the University of Texas Southwestern Medical Center at Dallas. He then joined the Harvard Stem Cell Institute as a postdoc fellow to study stem cells, genome editing and diabetes under the supervision of Drs. Andrew P. McMahon and Douglas A. Melton. In 2014, Dr. Xu joined Biogen to setup a HESC/iPSC platform focusing on the neurodegenerative diseases such as the Alzheimer’s, Parkinson’s, ALS, etc. Starting from 2016, Dr. Xu worked at Codiak BioSciences, the first biotech company focusing on exosome therapy. As a Director of Discovery, he led and participated in the establishment of engEX, a platform for exosome engineering, to support the IND of multiple pipelines at FDA. In 2021, as the founding CEO, Dr. Xu co-founded the VesiCURE Therapeutics Co. Ltd. At Suzhou, China.

Abstract: Precise drug delivery, especially those with clear functional mechanisms but low durgabilities, with low cytotoxicity has been a great challenge. Here, we propose to tackle the problem by employing a solution of utilizing exosomes, a nanoparticles harvested from native cells. The great therapeutic potential of low immunogenicity and tissue tropism has made exosome a wonderful candidate in shuttling various therapeutic payloads across biological barriers in a targeted manner.

Speakers
Peng Gao
(VP of Suzhou Abogen Biosciences Inc.)
Advances in mRNA Vaccine Technology

Biography: Peng Gao graduated from the Department of biology at Nankai University in 1995, and holds a PhD in Molecular Biology from the University of Texas in Austin. With 25 years of experience in the field of biomedical research and development, he has published over 20 papers in related areas such as vaccine development, antibody engineering, and enzyme engineering, and has applied for and been granted 4 patents. He joined Suzhou Abogen Biosciences as the vice president, responsible for the research and development of mRNA therapeutics.

Abstract: In recent years, mRNA vaccine technology has made significant progress and is completely transforming the field of vaccine research and development. Compared to traditional vaccines, mRNA vaccines have the advantage of a faster and more flexible production process and the ability to quickly respond to newly emerging infectious diseases. In this report, the latest advancements in mRNA vaccine technology will be explored, including its mechanism of action, process development and quality assessment. Additionally, the current status and future development directions of mRNA vaccines in treating various diseases, including COVID-19, will be discussed.

Speakers
Jing Huang
(Chairman of Next Vivo Suzhou Biotechnology Co., Ltd.)
Application of Humanized Immunity System Mice in the Development of Nano-Vaccine

Biography: Huang Jing, Founder and Chairman of Future Model (Suzhou) Technology Co., Ltd.and Genomab Biotech Corp

• In 2004, he graduated from Institute of Zoology, Chinese Academy of Sciences. From 2004 to 2006, he was a postdoctoral fellow at Peking University Health Science Center, and studied under Academician Tong Tanjun.

• Since 2006, he has been to the United States, working in world-renowned universities and institutes (Albert Einstein College of Medicine, Aaron Diamond AIDS Research Center and the Rockefeller University).

He has published 27 SCI articles (with the highest impact factor of 18 and the number of citations of more than 180).

He has developed various humanized animal models involving researches of tumor immunity, biological vaccines and infectious diseases, etc.

He has many years of experience in CRO and has assisted Leidos in the development of immune adjuvant (PD1 blocking protein) and USAID in the development of the MagaVax vaccine; He has also collaborated with the Institut Pasteur in the research of nanovaccines targeting dendritic cells, etc.

In January 2019, Dr. Huang founded Genomab Biotech Company in New York, focusing on the development of pharmaceutical-related mouse models. So far, he has applied for 3 patents and developed dozens of animal models and more than a dozen cell lines. In August 2021, he founded Future Model Company in Suzhou and was selected into the Leading Talent Incubation Program of Suzhou Industrial Park in the same year.

Abstract: Nanocarriers can not only increase the stability of mRNA vaccines, but also increase the efficiency of vaccine delivery targeting lymph nodes and dendritic cells through modification.The multiple humanized animal models developed by Future Model Suzhou Biotechnology Co., Ltd. have high abundance of human dendritic cells and lymph nodes, therefore the mouse models are expected to be used in the research and development of a variety of nanovaccines.

Speakers
Jingwei Zhu
( Qulity Director of Jiangsu Hillgene Biomedical Co., Ltd. )
The Testing Strategy and Sterile Rapid Testing of Original Supplementary Materials for Quasi-Commercial Cell Therapy Drug

Biography: 10+years of laboratory work experience, 6+years of biological testing laboratory work experience, involving the detection and release of monoclonal antibodies, cell therapy drugs IIT, IND and clinical stages, rich experience in GMP laboratory management and operation, responsible for the writing of QC part of multiple drug application materials, and experienced many pre-approval and periodic audits at home and abroad.

Abstract: The Detection strategies of cell drug raw materials and excipients in the late stage of clinical trial before BLA are shared, detection strategies of cell drug specific materials such as magnetic beads, lentivirus, apheresis and disposable consumables are discussed, and the regulatory requirements for sterile rapid detection and traditional method alternative verification unique to cell drugs are shared as well.

Speakers
Han Yuan
(Doctor of Innovent Biologics (Suzhou) Co., Ltd.)
TBD

Biography: TBD

Abstract: TBD

Speakers
Yunjun Wang
(Chairman & CEO of Suzhou Xingshuo Nanotech Co., Ltd. )
Quantum Dots Application for Biomedical Detection

Biography: YUNJUN WANG, Ph.D. of University of Alberta, Postdoctoral fellow of Stanford University, currently the chairman of SUZHOU XINGSHUO NANOTECH CO., LTD. He is the expert of the national major talent introduction projects, and has been selected into the “Jiangsu Provincial Talent Introduction Plan”, “Gusu Leading Talent Plan”. Dr. Wang has been engaged in quantum dots since 2002, he has published more than 40 professional research papers. He served as a member of the National Nanotechnology Standardization Technical Committee and participated in the formulation of two national standards. Series of quantum dot products by Dr. Wang have been used in scientific research and new product development by hundreds of universities, scientific research institutions and companies.

Abstract: Quantum dot (QD is a semiconductor nanocrystal that is small enough to exhibit quantum mechanical properties. Due to its excitons are confined in all three spatial dimensions, the properties of QDs are intermediate between those of bulk semiconductors and of discrete molecules. As a new generation of fluorescent materials, QDs are widely used in optics, electricity, magnetic media, medicine, life science, and functional materials. It is found that QD fluorescent materials usually have good thermal stability and dispersion, high fluorescence stability, high surface modifiability, and good biocompatibility. Meanwhile, QD magnetic fluorescent microspheres also have strong magnetic responsiveness, which can be widely used in biological detection, disease diagnosis, immune detection, high throughput drug screening and other biomedical fields.

Speakers
Huafen Liu
(Chairman & CEO of Hangzhou Calibra Diagnostics Co., Ltd. )
The Application of Nanomaterials in the Analysis of Proteins and Small Molecules in Biological Samples

Biography: Prof. Liu previously worked as a researcher at Pfizer, a scientist at Roche Pharmaceuticals, and North America/APAC Mass Spectrometry Application and Support Director, Global Director of the Innovative application Platform of Mass Spectrometry at SCIEX (Danaher Corp); She has published over 100 articles on international journals such as Cell, Cell Reports, etc. as well as in the international conferences; She was also invited to give keynote technical reports at international leading conferences multiple times due to leading research results; She won the 2016 Technical Excellent Award of the AOAC International for the innovative allergen protein methodology, which was validated in laboratories and promoted globally as First Action AOAC standard methodology.

Abstract: Nanoparticles have found many applications in the analysis of proteins and small molecules due to their unique properties such as high surface area-to-volume ratio, high stability, and ease of functionalization. For example, nanomaterials such as nanoparticles and nanowires can be functionalized with specific probes that can bind to proteins or metabolites of interest, thereby increasing the sensitivity and specificity of the method. This allows for the detection of low abundant proteins and metabolites that were previously difficult to detect using traditional analytical methods. Additionally, the use of nanomaterials in detecting proteins and small molecules also provides the potential for multiplexing, meaning the simultaneous analysis of multiple targets in a single sample, which is crucial for the understanding of complex biological systems. Therefore, the application of nanomaterials in the analysis of proteins and small molecules biological samples is a rapidly growing field that holds much promise for advancing our understanding of biological systems and for the development of new and improved analytical tools.

Speakers
Fei Xu
(Professor, University of Shanghai for Science and Technology)
The Sample Pretreatment for Food Rapid Testing

Biography: Prof. Xu Fei, PhD, Vice President of the Research Institute of Shanghai University of Science and Technology, Director of Shanghai Food Rapid Test Engineering Technology Research Center, has been awarded the program of Shanghai Academic/Technology Research Leader, Shanghai Rising-Star, and Shanghai May Day Labor Award, etc. Her research interest focuses on food quality and safety research. She has presided over 23 national/provincial vertical and horizontal research projects and won 7 provincial and ministerial research awards. Especially in the field of pesticide residue testing and devices, she had won the second prize of Shanghai Technical Invention Award in 2014, the second prize of China Machinery Industry Science and Technology Progress Award in 2007 and the third prize of Shanghai Technical Invention Award in 2006 (both ranked first) . In the past 5 years, she has published more than 50 high-level papers with total IF over 300; applied for 28 national invention patents, of which 7 were granted; published 1 monograph; revised 4 national food safety standards and recognized 4 fast-testing methods; organized and hosted three consecutive international conferences on food biotechnology and precision health.

Abstract: Efficient sample pretreatment techniques are important to achieve rapid and accurate determination of food safety hazards in different sample matrices. In recent years, according to the requirement of rapid testing method, we have developed series pre-treatment methods based on dual-frequency ultrasonic enzymatic digestion, QuEChERS-dispersive liquid-liquid microextraction, mesoporous molecularly imprinted sorbent materials, magnetic metal-organic framework extraction, etc. All these methods aiming at the binding state and presence form of heavy metals, pesticide and veterinary drug residues, etc. with the food matrix, matched with aptamers, antibodies, enzymes and other rapid detection recognition unites have been developed to achieve efficient enrichment and purification. To solve the existing safety rapid detection products / technology application scenarios are not targeted limitations.

Speakers
Xingda Ye
(Head of BioinformaticsAntibody Department of Shenzhen Jingtai Technology Co., Ltd. )
XploreSeq™——Explore Vast Antibody Sequence Space: NGS and AI Enabling Antibody Discovery

Biography: Xingda Ye holds a Bachelor’s degree in Biotechnology and a Master’s degree in Bioinformatics from Imperial College London. He has worked for renowned research institutions, pharmaceutical companies, and biotechnology firms such as GSK, Francis Crick Institute, and UWI, accumulating rich experience in interdisciplinary research in multi-omics data analysis and AI algorithm development. Currently, he serves as the head of the bioinformatics team in the Antibody Drug Department of Jingtai Technology, responsible for building the NGS+ML antibody discovery platform XploreSeq and developing and implementing machine learning models based on antibody sequence/omics data.

Speakers
Yiqiang Wang
(Professor, Xi'an Jiaotong-Liverpool University )
Application of Proteomics Technology in the Study of Novel Molecules and Pathways

Biography: Dr. Yiqiang Wang received a Bachelor degree in Basic Medicine from Beijing Medical University (now Health Science Center of Peking University) and a PhD degree in pathophysiology from the Academy of Military Medical Sciences. After postdoc training in the Second Military Medical University and the University of Iowa (1996-2003), he started his career track in the University of Iowa, Shandong Academy of Medical Sciences, Soochow University, Xiamen University and Xi’an Jiaotong-Liverpool University sequentially. His research is to understand the mechanisms underlying the pathogenesis or treatment of diseases. He published over 50 SCI-indexed papers plus over 50 papers in non-SCI-indexed journals. He also published two books and got nine patents. He is member of several journal editorial boards or academic societies.

Abstract: Advancement and popularization of proteomics technology greatly facilitates the research in the field of biomedicine, either in basic, translational or clinical medicine fields. Hence the discovery of novel molecules or novel pathways underlying the physiopathological processes is accelerated. By briefing the studies of host-pathogen interactions, platelets-endothelial cells interactions, or functional exploration of novel genes using proteomics strategies, this talk should demonstrate the roles of proteomics in the field of biomedicine.   

Speakers
Mi Liu
(Professor, Soochow University )
Study on Cancer Nano-Vaccine Reassembled from Whole Cell Components of Cancer Cells and Delivery of mRNA by Lipid Micro-Particles

Biography: Mi Liu received his M.S from the School of Pharmaceutical Sciences of Peking University in 2010, received his Ph.D from the Drug Formulation & Delivery lab in Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zürich (ETH Zürich) in Switzerland in 2014, and received postdoctoral training from Department of Immunobiology at Harvard Medical School. In December 2018, he joined the Institute of Pharmaceutics, College of Pharmaceutical Sciences, Soochow University as a professor.As the corresponding author or the first author, he has published papers in the high quality journals including Nature Communications, Advanced Materials, Advanced Functional Materials, Analytical Chemistry and iScience eta., and some papers have been published as cover and highlight papers.The research is practical and has close cooperation with pharmaceutical enterprises. Several projects have successfully transferred to pharmaceutical companies. As the first inventor, he has applied for more than 40 international invention patents and Chinese invention patents on preventive and therapeutic cancer vaccine, cancer cell specific detection technology, mRNA vaccine delivery technology and immune multi-target detection technology etc., among which 7 have been authorized. Some international invention patents have entered the United States, the European Union, Japan, Canada, South Korea, Australia and Brazil. 11 invention patents have been successfully transferred to biopharmaceutical enterprises.

Abstract: Cancer vaccine is one of the most important methods in cancer immunotherapy. Tumor tissue/cancer cell is the best antigen source for preparing cancer vaccine, this study reassembles the whole cell components of tumor tissue/cancer cell into nano-sized vaccine. Such cancer nanovaccines can effectively prevent and treat lung cancer, melanoma, liver cancer, breast cancer and other cancers and cancer metastasis. The cancer nanovaccines can effectively activate the tumor cell-specific T cells of the body, can effectively induce long-term immune memory, and produce cross-immune response across cancer species.Currently, the commonly used mRNA delivery strategy is lipid nanoparticles (LNP), but it encounters patent barriers, potential toxicity and other problems. The lipid microparticle (LMP), developed by our research group, can effectively avoid the patent barrier of LNP, we possess completely independent intellectual property rights. LMP has achieved the same effect as LNP in vitro and in vivo experiments, and has better lymph node targeting capacity.

Speakers
Mingxian Huang
(CSO of BEAVER Biomedical Engneering Co., Ltd.)
Magnetic Nanomaterails in Advanced In Vitro Diagnostic Technology: Preparation, Surface Modification, and Applications

Biography: Huang Mingxian, CSO of Beaver Biomedical Engineering Co., Ltd., received a bachelor’s degree from Hunan University, a master’s degree from Dalian Institute of chemical physics, a doctor’s degree from Brigham Young University, and then did postdoctoral research at Indiana University. Dr. Huang has worked in several high-tech companies in USA for nearly 20 years; after returning to China as a selected candidate of national major talent project, he has worked in Beijing, Tianjin, Zhengzhou and Shanghai for more than fifteen years. Dr. Huang is committed to the preparation and surface modification of micro- and nanomaterials for biological separation, biological detection, and biomedicine. He has published more than 50 papers and has more than 40 patents at home and abroad, and successfully developed a variety of new chromatographic packing materials and a series of functional magnetic materials, which are widely used in clinical diagnosis, drug analysis, biomedicine and other fields.

Abstract: Magnetic nanoparticles has become a key class of raw materials for immunoassay, nucleic acid extraction and molecular diagnosis in advanced in vitro diagnostic technology. The preparation and surface modification methods for these magnetic materials have evolved greatly in the last decade, which help promote the advancement of modern in vitro diagnostic technology, such as  COVID-19 detection chemiluminescence assaycell sortingdrug deliveryand magnetic mediated hyperthermia.

Speakers
Shiqi Ma
( Application Scientist of Suzhou ExCell Biotechnology Co., Ltd.)
New Trends in the Development of Cell Culture Media in the Field of Cell and Gene Therapy


Speakers
Jin Su
(Professor, Guangzhou Medical University )
The Fibrotic Disease Drived by Bioinformatics Big Data


Speakers
Yahui Guo
(Associate Professor, Jiangnan University)
Development of a Nucleic Acid Extraction Kit for Pathogenic Bacteria using Concave Soil Material


Speakers
Shancen Zhao
(Vice President of The Beijing Genomic Institute- Research)
Multi-Omics Based Tool Enzymes Exploration and Industrial Application


Speakers
Xiaodong Su
( Professor, Peking University)
Adeno-Associated Virus (AAV) and Gene Therapy and Antibody Drug Delivery

Biography: Professor Su Xiaodong: doctoral supervisor, outstanding youth of the National Foundation of the People’s Republic of China, Changjiang Distinguished Professor of the School of Life Sciences of Peking University, and executive deputy director of the Biomedical Frontier Innovation Center (BIOPIC) of Peking University. He is currently the Chairman of the Asian Crystal Association (AsCA); He has successively served as the president, secretary general and director of the macromolecular professional committee of the China Crystal Society (CCrS); Chairman of the macromolecular professional committee of the International Crystal Society (IUCr). He also served as the editorial board member of the international professional journal "Crystallography Reviews"; Editorial board of the internationally famous journal "Protein and Cell". Su Xiaodong graduated from the Department of Physics of Peking University (now the School of Physics) in 1985; In 1994, he received a doctorate of science from the Department of Cell and Molecular Biology, Karolinska Medical College, Sweden; From 1995 to 1998, he did postdoctoral research at Howard Hughes Institute of Medicine (HHMI), Department of Biology, California Institute of Technology (Caltech); From 1998 to 2002, he successively served as assistant professor and associate professor of the Chemistry Center of Lund University, Sweden; Since 2003, he has been employed as a professor of Changjiang (scholar) by the School of Life Sciences of Peking University, and won the National Science Fund for Distinguished Young Scholars in 2003.


Speakers
Zhixin Zhang
( Professor, University of Electronic Science and Technology of China / Chairman of Chengdu ExAb Biotechnology Co., Ltd.)
Early Cancer Screening Using Artificial Intelligence Assisted Immune Big Data Analyses (AIAIBDA)

Biography: Professor Zhixin Zhang graduated from Nankai University and served as a tenured professor at Nebraska Medical Center. In 2015, he returned to China full-time and was selected as a national special expert. Professor Zhang has long been engaged in the development of B lymphocytes and the molecular regulation of antibody gene recombination, as well as the research work of auto-antibodies, antiviral antibodies and anti-tumor antibodies. The results are published in world-class academic journals such as Nature Immunology / Natural Immunization, Immunity / Immunization, Blood / Blood, Immunol Review / Immunization Review, Trends Immunol / Immune Trends, J Biol Chem / Journal of Biochemistry, J Clinic Invest / Clinical Medicine Research, and PNAS / Proceedings of the American Academy of Sciences. After returning to China, Professor Zhang established a technology platform to analyze BCR / TCR gene diversity using high-throughput sequencing, using immune big data analysis to evaluate immunity, conduct early screening of cancers and diseases, predict and evaluate the treatment efficacy, and develop new technologies to treat cancers, all of which are the first in the world. 

Abstract: Chengdu ExAb Biotechnology LDT has established a mega immune database, and developed the Artificial Intelligence assisted Immune Big Data Analyses (AIAIBDA) system to detect early cancers and other diseases. Using the artificial intelligence analysis system to compare the immune data in the testing samples with the established characteristic immune signatures of different cancers, the AIAIBDA system can identify cancers and can also evaluate the progression of cancers. The AIAIBDA system is completely different from the conventional high-throughput gene sequencing to detect genetic mutations. The genetic mutations can only predict the risk of cancers or other diseases, but can not determine the occurrence and progression of cancers. It is very difficult to accurately detect early cancers using  free DNA fragments in the peripheral blood. The AIAIBDA system use the immune signatures as new biomarkers to identify cancers. The positive results indicate the occurrence of cancers in the body. The AIAIBDA system can detect very early cancers.

Speakers
Lin Guo
( CAR-NK Researcher of Innovent Biologics, Inc.)
Next Generation NK Cell Activation and Amplification System


Speakers
Hongchen Gu
( Professor, Shanghai Jiao Tong University )
Innovation Leads the Change- A New Cooperation Model in IVD Upstream and Downstream

Biography: Hongchen Gu is the professor and Director of Nano Biomedical Research Center, Med-X Research Institute, Shanghai Jiao Tong University. Dr. Hongchen Gu  received his Ph. D. in chemical engineering from East China University of Science and Technology. From July 2001 to Janurary 2005, Dr. Hongchen Gu worked as the Director of Engineering Research Center for Nano Science and Technology in Shanghai Jiaotong University. Before this, he was working as the Director of Key Laboratory of Nano Materials, Ministry of Education of  P.R.China.With more than twenty years study in nano materials area, Professor Gu proposed a systematic process development methodology for large scale synthesis of nano particles. By applying interface chemistry in the surface coating of nano particles, Prof. Gus group has successfully systhesized superparamanetic nano particles and is exploring their bio-med applications, such as bio molecular manipulation, diagnostics and targeted drug/gene delivery.


Speakers
Li Yu
(Professor, Tsinghua University)
Migrasome:Basic Biology and Herapeutic Potentials


Speakers
Chao Hong
(Associate Professor, Soochow University / Principal Engineer of BEAVER Biomedical Engneering Co., Ltd.)
Application of Immunomagnetic Beads in Cell Isolation and Activation

Biography Beaver Biomedical Engineering Co. Ltd (2022-)

Department of Laboratory Medicine, University of California San Francisco, USA, Postdoc (2015-2017)

Institutes of Biology and Medical Sciences, Soochow University, Lecturer/Associate professor (2010-)

Department of Immunology, Peking University, China, Ph.D. (2005-2010)

Department of Clinical Medicine, Zhengzhou University, China, M.D. (2000-2005)


Speakers
Heng Zhang
(Professor, Shanghai Jiao Tong University)
Developing Naturally Stress-Resistant Crops for a Sustainable Agriculture

Biography: 1999.9 – 2003.7, B.S., School of Life Sciences, Peking University

2003.8 – 2009.8, Ph.D., Department of Biochemistry, Purdue University

2009.9 – 2011.12, Postdoc, School of Agronomy, Purdue University

2012.1 – 2014.5, Junior Group Leader, Shanghai Center for Plant Stress Biology, Chinese Academy of Sciences

2014.6 – 2023.2, Principal Investigator, Shanghai Center for Plant Stress Biology, Chinese Academy of Sciences

2023.3 – present, Principal Investigator, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University

Abstract: Extremophytes, plants that thrive in harsh environments such as deserts and seawater, are excellent models for studying abiotic stress resistance in plants. Some extremophytes, such as quinoa and broomcorn millet, were domesticated as crops by human ancestors. These so-called naturally stress-resistant crops (NSRCs) have great potential in improving food security through diversifying the agriculture and ensure yield stability, especially in the face of global climate change. Elucidating the molecular mechanisms underlying extreme stress resistance in these plants can also help improve stress resistance in main crops. We used genomics-based approaches to study the evolution of NSRCs and delineate the genetic bases of important agronomic traits.

专业观众登记入口 立即报名
© 苏州纳米科技发展有限公司版权所有 苏ICP备15009858号-1  Technical Support: